Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease VIVIAD Phase 2b study in Europe on track for final data readout Q1/2024Data
DGAP-News: Vivoryon Therapeutics N.V. / Key word: Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in. | October 18, 2021
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development